Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
May 05,2022
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.
More
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
May 05,2022
Lockdown Never Stopped; Resumption of Work Increases Efficiency
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work.
More
Lockdown Never Stopped; Resumption of Work Increases Efficiency
Apr 27,2022
Medicilon was selected into the Biomedicine Index
Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.
More
Medicilon was selected into the Biomedicine Index
Apr 27,2022
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
On April 20th, the 2021 Drug Innovation Award sponsored by Securities Times, Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award.
More
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
Apr 27,2022
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
On March 9, the "Hi Liquid Workplace" 2021 China Annual Best Employer Awards Ceremony of the Yangtze River Delta region ended successfully online. Shanghai Medicilon Inc. (Medicilon) won the "Top 50 China Best Employer Award 2021."
More
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
Apr 27,2022
Medicilon was selected as a constituent stocks of the STAR 50 Index
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.
More
Medicilon was selected as a constituent stocks of the STAR 50 Index
Apr 19,2022
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Medicilon is deeply aware of its responsibilities toemployees, pharmaceutical companies and scientific research institutions, and even for the entire biopharmaceutical industry chain as an integrated prclinial R&D facility.
More
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Apr 19,2022
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Shanghai Medicilon Inc. announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon.
More
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Mar 14,2022
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Shanghai Medicilon Inc. (Medicilon) provided GLP-compliant toxicology DRF tests and application materials for the research and development of YY001, which accelerating the project to get into Phase 1 clinical trials.
More
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Mar 02,2022
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
On February 22, Shanghai Medicilon Inc (Medicilon)'s partner Imbioray (Hangzhou) Biomedicine Co., Ltd. (Imbioray) announced the completion of RMB 230 million Round A financing.
More
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
Feb 28,2022
Medicilon Won Praise and Awards From Many Partners
Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project.
More
Medicilon Won Praise and Awards From Many Partners
Feb 18,2022
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Zhenrong Guo as the Executive Vice President of VCMC(APIs + Preparations).
More
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC